# Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

> **NCT04454398** · PHASE1 · WITHDRAWN · sponsor: **Sorrento Therapeutics, Inc.**

## Conditions studied

- Covid-19

## Interventions

- **BIOLOGICAL:** COVI-GUARD
- **OTHER:** Standard of Care
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04454398
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2021-01
- **Final completion:** 2021-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty recruiting
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04454398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04454398, "Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04454398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*